• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    General Counsel Ferguson Jeffrey W. was granted 1,368 shares, increasing direct ownership by 0.12% to 1,097,293 units (SEC Form 4)

    5/29/25 5:09:59 PM ET
    $CG
    Investment Managers
    Finance
    Get the next $CG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Ferguson Jeffrey W.

    (Last) (First) (Middle)
    1001 PENNSYLVANIA AVENUE, NW

    (Street)
    WASHINGTON DC 20004

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Carlyle Group Inc. [ CG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    05/27/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/27/2025 A(1) 1,368 A $0 1,097,293 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents dividend equivalent units accrued on certain existing time-vesting restricted stock unit awards, the grant of which was previously reported, in connection with the issuer's quarterly dividend. Such dividend equivalent units will vest on the same schedule and subject to the same terms and conditions as the underlying awards.
    Remarks:
    /s/ Anne K. Frederick by power of attorney for Jeffrey W. Ferguson 05/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CG

    DatePrice TargetRatingAnalyst
    5/14/2025$56.00Hold → Buy
    TD Cowen
    3/19/2025Outperform → Perform
    Oppenheimer
    1/3/2025$60.00Peer Perform → Outperform
    Wolfe Research
    9/12/2024$42.00Equal Weight
    Wells Fargo
    8/27/2024$55.00Buy
    Redburn Atlantic
    8/6/2024$46.00 → $44.00Overweight → Neutral
    JP Morgan
    1/19/2024$40.00 → $41.00Buy → Neutral
    Citigroup
    1/4/2024$42.00Market Perform
    TD Cowen
    More analyst ratings

    $CG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

      All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right ("CVR") if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December

      5/30/25 8:30:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • Resonetics® Invests in Nitinol Gun Drilling Capabilities Through Purchase of Assets from Medical Component Specialists

      Establishes nitinol input tube operation to support premium, implant-grade tubing initiative and strengthen supply chain resilience NASHUA, N.H., May 19, 2025 /PRNewswire/ -- Resonetics® announced today that it has acquired the nitinol gun drilling operations and related assets of Medical Component Specialists' (MCS) New Boston, NH facility.  This acquisition marks another key investment in Resonetics' comprehensive U.S.-based nitinol strategy. This transaction follows the meaningful steps that Resonetics has taken to expand the availability of material and supply of nitinol, a crucial material for the most innovative next generation medical devices.

      5/19/25 10:00:00 AM ET
      $CG
      Investment Managers
      Finance
    • Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

      Stockholders that have previously tendered their shares must re-tender their shares Stockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achievement of a net sales milestone or $5.00 per share with no CVR As previously announced on May 14, 2025, Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird"), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated instructions for stockholders to tender their shares into the offer. Updated Instructions

      5/16/25 4:30:00 PM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance

    $CG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

      SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)

      11/15/24 5:22:29 PM ET
      $CG
      Investment Managers
      Finance
    • Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

      SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

      10/21/24 4:31:27 PM ET
      $CG
      Investment Managers
      Finance
    • Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

      SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

      10/15/24 4:31:27 PM ET
      $CG
      Investment Managers
      Finance

    $CG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Ferguson Jeffrey W. was granted 1,368 shares, increasing direct ownership by 0.12% to 1,097,293 units (SEC Form 4)

      4 - Carlyle Group Inc. (0001527166) (Issuer)

      5/29/25 5:09:59 PM ET
      $CG
      Investment Managers
      Finance
    • Chief Executive Officer Schwartz Harvey M was granted 31,709 shares, increasing direct ownership by 0.51% to 6,188,889 units (SEC Form 4)

      4 - Carlyle Group Inc. (0001527166) (Issuer)

      5/29/25 5:09:50 PM ET
      $CG
      Investment Managers
      Finance
    • Chief Accounting Officer Andrews Charles Elliott Jr. was granted 302 shares, increasing direct ownership by 0.21% to 144,121 units (SEC Form 4)

      4 - Carlyle Group Inc. (0001527166) (Issuer)

      5/29/25 5:09:40 PM ET
      $CG
      Investment Managers
      Finance

    $CG
    SEC Filings

    See more
    • The Carlyle Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders

      8-K - Carlyle Group Inc. (0001527166) (Filer)

      5/30/25 5:19:46 PM ET
      $CG
      Investment Managers
      Finance
    • Amendment: SEC Form SCHEDULE 13G/A filed by The Carlyle Group Inc.

      SCHEDULE 13G/A - Carlyle Group Inc. (0001527166) (Subject)

      5/13/25 11:44:13 AM ET
      $CG
      Investment Managers
      Finance
    • SEC Form 13F-HR filed by The Carlyle Group Inc.

      13F-HR - Carlyle Group Inc. (0001527166) (Filer)

      5/9/25 4:37:58 PM ET
      $CG
      Investment Managers
      Finance

    $CG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Carlyle Group upgraded by TD Cowen with a new price target

      TD Cowen upgraded Carlyle Group from Hold to Buy and set a new price target of $56.00

      5/14/25 8:48:54 AM ET
      $CG
      Investment Managers
      Finance
    • Carlyle Group downgraded by Oppenheimer

      Oppenheimer downgraded Carlyle Group from Outperform to Perform

      3/19/25 8:14:15 AM ET
      $CG
      Investment Managers
      Finance
    • Carlyle Group upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Carlyle Group from Peer Perform to Outperform and set a new price target of $60.00

      1/3/25 7:19:04 AM ET
      $CG
      Investment Managers
      Finance

    $CG
    Financials

    Live finance-specific insights

    See more
    • Carlyle Secured Lending, Inc. Announces Financial Results For First Quarter Ended March 31, 2025, Declares Second Quarter 2025 Dividend of $0.40 Per Common Share

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its first quarter ended March 31, 2025. Justin Plouffe, CGBD's Chief Executive Officer, said, "Following successful completion of the merger with CSL III at the end of March, CGBD remains focused on driving stable income, consistent credit performance, and disciplined execution of our strategy. Complementing our conservative investing approach, we continue to optimize the capital structure of CGBD, increasing total commitments on our credit facility and exchanging the pre

      5/6/25 4:05:00 PM ET
      $CG
      $CGBD
      Investment Managers
      Finance
      Finance: Consumer Services
    • Carlyle Credit Income Fund Schedules Second Quarter Financial Results and Investor Conference Call

      NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Tuesday, May 20, 2025, for its second quarter of 2025. CCIF will host a conference call at 10:00 a.m. EST on Wednesday, May 21, 2025, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally managed closed-end f

      4/16/25 4:46:22 PM ET
      $CCIF
      $CG
      Finance/Investors Services
      Finance
      Investment Managers
    • Carlyle Secured Lending, Inc. Schedules Earnings Release and Quarterly Earnings Call to Discuss its Financial Results for the First Quarter Ended March 31, 2025

      NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. ("Carlyle Secured Lending") (NASDAQ:CGBD) will host a conference call at 11:00 a.m. EST on Wednesday, May 7, 2025 to announce its financial results for the first quarter ended March 31, 2025. The Company will report its quarterly financial results on Tuesday, May 6, 2025. The conference call will be available via public webcast via a link on Carlyle Secured Lending's website at carlylesecuredlending.com and will also be available on the website soon after the call's completion. About Carlyle Secured Lending, Inc. Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ:CGBD) business development company (

      4/15/25 4:25:17 PM ET
      $CG
      $CGBD
      Investment Managers
      Finance
      Finance: Consumer Services

    $CG
    Leadership Updates

    Live Leadership Updates

    See more
    • SoftBank Group to Acquire Ampere Computing

      SoftBank Group Corp. (TSE: 9984, "SoftBank Group") today announced that it will acquire Ampere® Computing, a leading independent silicon design company, in an all-cash transaction valued at $6.5 billion. Under the terms of the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group and retain its name. As part of the transaction, Ampere's lead investors – Carlyle (NASDAQ:CG) and Oracle Corp. (NYSE:ORCL) – are selling their respective positions in Ampere. As SoftBank Group broadens its AI infrastructure investments in ventures such as Cristal intelligence and Stargate, the acquisition will help enhance SoftBank Group's capabilities in key areas and accelerate its growt

      3/19/25 7:30:00 PM ET
      $CG
      $ORCL
      Investment Managers
      Finance
      Computer Software: Prepackaged Software
      Technology
    • Acentra Health Welcomes Distinguished Public Sector Health Leaders Calder Lynch and Jami Snyder to its Healthcare Advisory Board; Appoints Julie Boughn as New Chair

      MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, today announced the appointment of Calder Lynch and Jami Snyder to its healthcare advisory board. With decades of experience leading state and federal government healthcare programs, the subject matter experts will advise the company and its clients on healthcare policies and trends as well as strategies to improve health outcomes at a lower cost. "We are excited to welcome Calder Lynch and Jami Snyder to Acentra Health's Healthcare Advisory Boar

      2/4/25 9:58:04 AM ET
      $CG
      Investment Managers
      Finance
    • Acentra Health Appoints Ezmeralda Sager as Chief Transformation Officer

      MCLEAN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced it has appointed Ezmeralda Sager as Executive Vice President and Chief Transformation Officer (CTO), effective January 6, 2025. In this role, Sager will spearhead enterprise-wide change initiatives to help Acentra Health build upon its strong track record of innovation and execution for its clients. She will provide strategic guidance on process improvements to optimize the development and delivery of the company's products, solutions

      1/23/25 9:42:00 AM ET
      $CG
      Investment Managers
      Finance